Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

Mary Pat Lancelotta

Mary Pat Lancelotta is currently the Senior Vice President of the MRD BioPharma business at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Mary Pat brings over 20 years of commercial and strategy experience in life sciences and diagnostics with a focus in oncology, and she has held leadership roles in both start-ups and Fortune 500 companies. She previously served as Vice President Strategic Marketing at Foundation Medicine where she launched FoundationOne and FoundationOne Heme, and also led strategic communications through several rounds of financing, including the IPO and acquisition by Roche. She came to FMI from Quest Diagnostics where she led commercial strategic planning for the company’s $5B laboratory services business and served as chief-of-staff to the Chief Medical Officer. Earlier in her career, Mary Pat spent seven years in consulting with Accenture and The Frankel Group, a boutique life sciences consulting firm. She has been a strategic consultant to several early stage oncology/early detection diagnostic companies. Additionally, she serves or has served on the board of directors for two private companies, Molecular Match and Ultivue, as well as Target Cancer Foundation, a non-profit advancing clinical research for rare cancers. Mary Pat holds an MBA with honors from Columbia Business School and a BS in Biochemistry, magna cum laude, from Boston College.

Stacy Taylor

Stacy Taylor is the Senior Vice President, General Counsel of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. As General Counsel, Stacy leads Adaptive’s legal functions, including strategic transactions; commercial contracting; corporate governance; and compliance with healthcare, privacy and securities laws, as well as the protection, enforcement and strategic monetization of Adaptive’s intellectual property assets. She is a registered patent attorney with decades of business law and litigation experience. Stacy was previously a partner in several major law firms, most recently DLA Piper, where she co-chaired the firm’s global medical device practice. She has also served as senior assistant general counsel for five business units at BTG International (now Boston Scientific), a life sciences product company. In the late 1990s, Stacy co-founded Endicor Medical, an interventional cardiology device company which was later acquired by Medtronic. Stacy holds degrees in biological sciences and chemistry from California Polytechnic State University and is registered to practice law in Washington and California.

Susan Bobulsky

Susan Bobulsky is the Chief Commercial Officer, MRD, at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Before this, she served in commercial and strategic planning roles of ascending responsibility since joining Adaptive in September 2014. Prior to joining Adaptive, Susan was an Associate Principal with ZS Associates, a healthcare management consulting firm, where she worked for nine years specializing in commercialization strategy and execution for therapeutic and diagnostic products. Susan holds an MBA from the Stanford Graduate School of Business and a BS in Science, Technology and Society from Stanford University.

Yi Zhou

Yi Zhou is the Chief Technical Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Yi is a proven leader with successful experience building world-class organizations, with over 25 years of experience leading IT in a global environment, building enterprise systems, data analytics platforms and highly regulated medical device products. Before joining Adaptive, Yi led a variety of large-scale digital health initiatives at GE Healthcare and won the GE CEO award. Prior to that, Yi took on various senior leadership roles at Quest Diagnostics and Celera. Yi holds two master’s degrees – Microbiology from the University of Kansas and Computer Science from the University of Missouri. Yi also has a bachelor’s degree in Microbiology from Fudan University and four professional certificates in Agile process and software development.

Francis Lo

Francis Lo is the Chief People Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Francis brings a unique, multi-disciplinary perspective to leading People and Culture at Adaptive. Prior to joining Adaptive, Francis served as Vice President of Human Resources at Whole Foods Market. Previously, he also held leadership roles at Starbucks, including as Director of Global Talent Management and as Dean of Starbucks China University. In addition to his HR experience, Francis has worked in CPG Sales, Strategy, Consumer Insights, and Shopper Marketing, and he has served on the boards of multiple Non-Profit Organizations. Francis holds an MBA from Stanford University Graduate School of Business and a BA in the Plan II Honors Program from the University of Texas at Austin.

Sharon Benzeno, PhD

Dr. Sharon Benzeno is the Chief Commercial Officer, Immune Medicine and leads the Drug Discovery group of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Before joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon co-led the oncology business unit at Capgemini SE, a consulting and technology services company. Sharon came to Elsevier from Capgemini, where she served in a variety of management roles at AstraZeneca plc. Sharon holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from New York University Stern School of Business and a BA in Biochemistry from New York University. Sharon completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.

Tycho Peterson

Tycho Peterson is the Chief Financial Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Tycho brings several decades of financial leadership and experience within the life science and diagnostic industries to Adaptive. Prior to joining Adaptive, Tycho spent 23 years at JP Morgan Chase, where he was most recently the managing director of life science tools and diagnostics in the healthcare group. He holds an MSc/MBA degree in biology and business administration from the University of Oxford and a BS in biology from Cornell University.

Julie Rubinstein

Julie Rubinstein is the President of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since 2011, she has held a variety of leadership roles and currently oversees Life Sciences Research, Clinical Diagnostics, Drug Discovery, Corporate Marketing and Business Development functions. Julie was part of the executive team that took the company public in 2019.

Prior to joining Adaptive, Julie held various worldwide commercial development roles at Pfizer Oncology, primarily focusing on cancer immunotherapy. She also held multiple positions at Johnson & Johnson’s Ethicon Endo-Surgery division, where she helped commercialize a breast cancer diagnostic device in major European markets. She began her career in Morgan Stanley’s Global Health Care Group as a financial analyst. She currently serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York. Julie holds a dual degree, summa cum laude and Phi Beta Kappa, from the University of Pennsylvania’s Undergraduate Wharton School and Annenberg School of Communications, with a minor in French. She also holds an MBA from Harvard Business School.

Harlan Robins

Dr. Harlan Robins is the Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease.

Prior to co-founding Adaptive, Harlan served in various roles at the Fred Hutchinson Cancer Research Center (FHCRC) in the Computational Biology Program, including Assistant Faculty Member, Associate, and Full Member and Head of the program.

Harlan holds a BS in Physics from Harvard University and a master’s degree and PhD in Physics from the University of California, Berkeley, with a visiting appointment to the California Institute of Technology. Harlan received postdoctoral appointments in the particle theory group at the Weizmann Institute of Science in Israel.

Interested in the mathematics behind genetics and observing the potential utility of high-level mathematics to study problems in the biological sciences, Harlan took another postdoctoral appointment at the Institute for Advance Study in Princeton under famed biologist Dr. Arnold Levine. With Dr. Levine, he concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his faculty appointment at FHCRC in the Computational Biology Group, Public Health Sciences and Human Biology Divisions.

Chad Robins

Chad Robins is the chief executive officer and co-founder of Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease.

Since its founding in 2009, Chad has led Adaptive in building a proprietary immune medicine platform that fuels businesses across life sciences research, clinical diagnostics, and drug discovery. In 2019, Chad guided the company through its initial public offering, which was one of the year’s most successful biotech IPOs. Under his leadership, Adaptive has successfully launched the clinical diagnostic clonoSEQ®, the first and only FDA-authorized NGS-based test to detect and monitor minimal residual disease in certain B-cell cancers.

Chad has also propelled Adaptive into the burgeoning health tech space, forging a partnership with tech giant Microsoft, and bringing cloud computing and machine learning together with Adaptive’s technology to map the immune response of many diseases. This work fuels a pipeline of diagnostic tests across cancer, autoimmune disorders, and infectious disease. Adaptive is also working to discover potent neutralizing antibodies to potentially prevent and treat COVID-19.

Chad is routinely recognized for excellence and innovation. In 2019 and 2020, he was included in the Puget Sound Business Journal’s Power 100, and Chad has been named a Goldman Sachs Most Intriguing Entrepreneur each year since 2015. He also received the 2016 Ernst & Young Entrepreneur of the Year® – The Pacific Northwest Region Award.  Adaptive was awarded Seattle Business Magazine’s Leaders in Health Care 2020 – Achievement in Medical Technology, as well as the Deloitte Technology Fast 500 each year since 2016. In addition, under Chad’s leadership, Adaptive has consistently been voted Best Places to Work by the Puget Sound Business Journal.

Chad is actively engaged in the biotech and health policy communities, serving on the executive board of Life Science Washington and the steering committee of the Coalition for 21st Century Medicine. In addition to serving as Chairman of the Board for Adaptive, he also holds board positions with AltPep, AdvaMedDx, and HeadLight.

Chad graduated with honors from Cornell University and obtained his MBA from The Wharton School at the University of Pennsylvania. Prior to Adaptive, Chad held executive-level positions in real estate, investment banking, private equity, and medical technology.